Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker GRAL
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 10, 2026 | SCHEDULE 13G | GRAL GRAIL, Inc. | State Street Corporation | 2.02M | 4.5% | SCHEDULE 13G ↗ |
| Nov 5, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | Primecap Management Co/Ca/ | 2.22M | 5.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | Mark C. Wehrly | 4.16M | 9.6% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | John R. Warren | 4.16M | 9.6% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | Andrew J. M. Spokes | 4.16M | 9.6% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | Daniel S. Short | 4.16M | 9.6% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | Edric C. Saito | 4.16M | 9.6% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | Roberts, Jr., Thomas G. | 4.16M | 9.6% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | Luo Patrick (Cheng) | 4.16M | 9.6% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | Michael G. Linn | 4.16M | 9.6% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | David T. Kim | 4.16M | 9.6% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | Avner A. Husen | 4.16M | 9.6% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | Nicolas Giauque | 4.16M | 9.6% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | Varun N. Gehani | 4.16M | 9.6% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | Hannah E. Dunn | 4.16M | 9.6% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | Philip D. Dreyfuss | 4.16M | 9.6% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | Joshua J. Dapice | 4.16M | 9.6% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | Farallon Healthcare Partners (GP), L.L.C. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | Farallon F5 (GP), L.L.C. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | Farallon Institutional (GP) V, L.L.C. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | Farallon Partners, L.L.C. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | Farallon Healthcare Partners Master, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | Farallon Capital F5 Master I, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | Farallon Capital (AM) Investors, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | Farallon Capital Offshore Investors II, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | Four Crossings Institutional Partners V, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | Farallon Capital Institutional Partners III, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | Farallon Capital Institutional Partners II, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | Farallon Capital Institutional Partners, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | Farallon Capital Partners, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | Farallon Capital Management, L.L.C. | 4.16M | 9.6% | SCHEDULE 13G/A ↗ |
| Aug 7, 2026 | SCHEDULE 13G | GRAL GRAIL, Inc. | State Street Corporation | 2.39M | 5.6% | SCHEDULE 13G ↗ |
| Aug 6, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | Primecap Management Co/Ca/ | 21.80M | 5.1% | SCHEDULE 13G/A ↗ |
| Jul 28, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | BlackRock, Inc. | 3.38M | 7.9% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | Felix J. Baker | 4.03M | 9.8% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | Julian C. Baker | 4.03M | 9.8% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | Baker Bros. Advisors (GP) LLC | 4.03M | 9.8% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | Baker Bros. Advisors LP | 4.03M | 9.8% | SCHEDULE 13G/A ↗ |
| May 11, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | Mark C. Wehrly | 3.25M | 7.8% | SCHEDULE 13G/A ↗ |
| May 11, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | John R. Warren | 3.25M | 7.8% | SCHEDULE 13G/A ↗ |
| May 11, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | Andrew J. M. Spokes | 3.25M | 7.8% | SCHEDULE 13G/A ↗ |
| May 11, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | Daniel S. Short | 3.25M | 7.8% | SCHEDULE 13G/A ↗ |
| May 11, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | Edric C. Saito | 3.25M | 7.8% | SCHEDULE 13G/A ↗ |
| May 11, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | Roberts, Jr., Thomas G. | 3.25M | 7.8% | SCHEDULE 13G/A ↗ |
| May 11, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | Luo Patrick (Cheng) | 3.25M | 7.8% | SCHEDULE 13G/A ↗ |
| May 11, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | Michael G. Linn | 3.25M | 7.8% | SCHEDULE 13G/A ↗ |
| May 11, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | David T. Kim | 3.25M | 7.8% | SCHEDULE 13G/A ↗ |
| May 11, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | Avner A. Husen | 3.25M | 7.8% | SCHEDULE 13G/A ↗ |
| May 11, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | Nicolas Giauque | 3.25M | 7.8% | SCHEDULE 13G/A ↗ |
| May 11, 2026 | SCHEDULE 13G/A (amended) | GRAL GRAIL, Inc. | Varun N. Gehani | 3.25M | 7.8% | SCHEDULE 13G/A ↗ |
Full history on every feed is part of Premium. Premium loads older rows, up to 10,000, and CSV downloads.
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 6:42 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances